Hepatitis C

Hepatitis C be an infectious disease wey be caused by de hepatitis C virus (HCV) wey primarily dey affect de liver; e be a type of viral hepatitis. During de initial infection period, people often get mild anaa no symptoms. Early symptoms fi include fever, dark urine, abdominal pain, den jaundice. De virus dey persist insyd de liver, wey cam be chronic, insyd about 70% of those wey initially be infected. Updated as required. Early on, chronic infection typically get no symptoms. Over chaw years however, e often dey lead to liver disease den occasionally cirrhosis. Insyd sam cases, those plus cirrhosis go develop serious complications such as liver failure, liver cancer, anaa dilated blood vessels insyd de esophagus den stomach.

HCV be spread primarily by blood-to-blood contact dem associate plus injection drug use, poorly sterilized medical equipment, needlestick injuries insyd healthcare, den transfusions. Insyd regions wer na dem implement blood screening, na de risk of contracting HCV from a transfusion drop substantially to less dan one per two million. HCV sanso fi be spread from an infected mommie to ein baby during birth. E no be spread thru breast milk, chow, water, anaa casual contact such as hugging, kissing, den dey share chow anaa drinks plus an infected person. Updated as required. E be one of five known hepatitis viruses: A, B, C, D, den E. Diagnosis be by blood testing to look for either antibodies to de virus anaa viral RNA. Insyd de United States, screening for HCV infection be recommended in all adults age 18 to 79 years old. Der be no vaccine against hepatitis C. Prevention dey include harm reduction efforts among people wey dey inject drugs, testing donated blood, den treatment of people plus chronic infection. Chronic infection fi be cured more dan 95% of de time plus antiviral medications such as sofosbuvir anaa simeprevir. Na Peginterferon den ribavirin be earlier generation treatments wey na dem prove successful insyd <50% of cases wey na dem cause greater side effects. While na access to de newer treatments be expensive, by 2022 na prices drop dramatically insyd chaw countries (primarily low-income den lower-middle-income countries) secof de introduction of generic versions of medicines. Those wey develop cirrhosis anaa liver cancer fi require a liver transplant. Hepatitis C be one of de leading reasons for liver transplantation. However, de virus usually dey recur after transplantation.

Na an estimated 58 million people worldwide be infected plus hepatitis C insyd 2019. Approximately 290,000 deaths from de virus, mainly from liver cancer den cirrhosis attribute to hepatitis C, sanso occur insyd 2019. De existence of hepatitis C – originally identifiable per as a type of non-A non-B hepatitis – na dem suggest insyd de 1970s wey dem prove insyd 1989. Hepatitis C dey infect humans den chimpanzees per.

 References 

 External links 





Category:Health care-associated infections
Category:Infectious causes of cancer
+C
Category:Translated from MDWiki
Category:Articles wey dey contain video clips